Ventyx Biosciences Files Q1 2025 10-Q Report
| Field | Detail |
|---|---|
| Company | Ventyx Biosciences, Inc. |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, biotech
TL;DR
Ventyx Biosciences filed its Q1 2025 10-Q. Check financials.
AI Summary
Ventyx Biosciences, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported financial results and provided updates on its operations. Key financial data and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial health and operational status of Ventyx Biosciences, Inc., crucial for understanding its current performance and future prospects.
Risk Assessment
Risk Level: medium — As a biotech company, Ventyx faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-05-08 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Ventyx Biosciences, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Date of filing
- SAN DIEGO, CA (location) — Company's business and mailing address
- Neurocrine Biosciences, Inc. (company) — Mentioned in relation to a sublease agreement
FAQ
What is the primary business of Ventyx Biosciences, Inc.?
Ventyx Biosciences, Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
What is the fiscal year end for Ventyx Biosciences, Inc.?
The fiscal year end for Ventyx Biosciences, Inc. is December 31 (1231).
Where is Ventyx Biosciences, Inc. located?
Ventyx Biosciences, Inc. is located at 12790 El Camino Real, Suite 200, San Diego, CA 92130.
What specific period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
Is there any mention of specific drug candidates or development programs?
The filing mentions 'VTX3232' in the context of the period from January 1, 2024, to March 31, 2024, suggesting it is a development candidate or program.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Ventyx Biosciences, Inc..